The Safety and Efficacy of Diphencyprone for the Treatment of Alopecia Areata in Children
Authors:
- Jennifer M. SalsbergJSJennifer M. Salsberg
- Jeff DonovanJDJeff Donovan
Open Access
- 1 September 2012
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 148 (9) , 1084-1085
Abstract
Topical diphencyprone (DPCP) immunotherapy is used to treat refractory and advanced alopecia areata. Although not approved for this indication by the US Food and Drug Administration, the safety and efficacy of DPCP in adults with alopecia areata has been evaluated in several studies. However, the use of DPCP in children has been the focus of only a limited number of studies. One study of 26 children indicated cosmetically acceptable hair regrowth in 35% of patients.1 A second study of 12 patients indicated hair regrowth in 67% of patients.2Keywords
This publication has 2 references indexed in Scilit:
- Treatment of Alopecia Areata in ChildrenPediatric Annals, 2009
- Alopecia areata in children:, response to treatment with diphencyproneBritish Journal of Dermatology, 1991